Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,otherCurrentLiab,netReceivables,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ENOB,-4214514.0,47613400,1079607,,-4031559,,-4030710,1943498,0,-3053930,-3053930,,-96347,,,,-849,0,3053930,0,-977629,,-4030710,-4030710,154893225.0,235875627.0,11378787.0,162318711.0,173697498.0,4780.0,-73548774.0,2951599.0,11640000.0,-12922.0,30484.0,4526284.0,1408253.0,-12922.0,2212618.0,4921171.0,5704840.0,504862.0,,,315938.0,-181794.0,3439007.0,-170397.0,3620801.0,1101234.0,-6925.0,-2330848.0,30824.0,1449223.0,,,,3512918.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NCM,"Enochian Biosciences, Inc.",us_market,2,NasdaqCM,"Enochian Biosciences, Inc.",USD,2239195,448500,4.83,1.8576924,2.6 - 12.99,-5.56,-0.42802155,2.6,12.99,1589227200,1589227200,1589227200,-0.235,0,3.463,5.555278,1.874722,0.33746684,4.445942,2.984058,0.67118686,353767552,2.1455386,15,America/New_York,EDT,-14400000,False,False,0.6775029,7.34 - 7.5,7.38,7.44,7.49,8,12,finmb_549849556,7.43,1630509299,0.049999714,7.37,7.5,7.34,64273,0.3,,,12.99,2.6,5.56,4.45,2.24M,448.5k,47.61M,,18.29M,61.79%,5.03%,1.16M,3.87,9.96%,2.23%,1.09M,,,,,,0.00%,,,,,"Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-4.25%,-8.09%,,,,,-11.93M,-13.46M,-0.23,,4.53M,0.09,7.61M,4.69,3.49,3.46,-9.83M,-5.87M,Value,90067-2012,Healthcare,10,8,10,"Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",Los Angeles,786 888 1685,CA,2,1609372800,1625097600,10,United States,http://www.enochianbio.com,86400,9,Century City Medical Plaza,Biotechnology,Suite 906 2080 Century Park East
t-1,ENOB,-4599297.0,47613400,1334468,,-2934454,,-2933296,1939988,0,-3305216,-3305216,,-93426,,,,-1158,0,3305216,0,370762,,-2933296,-2933296,154900139.0,231457324.0,10944588.0,161940842.0,172885430.0,4676.0,-69518064.0,2069101.0,11640000.0,-3094.0,30484.0,3425050.0,1558615.0,-3094.0,2306729.0,4008078.0,5928744.0,188924.0,484786.0,,-93452.0,-122464.0,-40408.0,493236.0,82056.0,-2540611.0,6681.0,-2496163.0,30760.0,-67390.0,-10721.0,-10721.0,,2449463.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NCM,"Enochian Biosciences, Inc.",us_market,2,NasdaqCM,"Enochian Biosciences, Inc.",USD,2239195,448500,4.83,1.8576924,2.6 - 12.99,-5.56,-0.42802155,2.6,12.99,1589227200,1589227200,1589227200,-0.235,0,3.463,5.555278,1.874722,0.33746684,4.445942,2.984058,0.67118686,353767552,2.1455386,15,America/New_York,EDT,-14400000,False,False,0.6775029,7.34 - 7.5,7.38,7.44,7.49,8,12,finmb_549849556,7.43,1630509299,0.049999714,7.37,7.5,7.34,64273,0.3,,,12.99,2.6,5.56,4.45,2.24M,448.5k,47.61M,,18.29M,61.79%,5.03%,1.16M,3.87,9.96%,2.23%,1.09M,,,,,,0.00%,,,,,"Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-4.25%,-8.09%,,,,,-11.93M,-13.46M,-0.23,,4.53M,0.09,7.61M,4.69,3.49,3.46,-9.83M,-5.87M,Value,90067-2012,Healthcare,10,8,10,"Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",Los Angeles,786 888 1685,CA,2,1609372800,1625097600,10,United States,http://www.enochianbio.com,86400,9,Century City Medical Plaza,Biotechnology,Suite 906 2080 Century Park East
t-2,ENOB,-2310598.0,47613400,1050376,,-2519364,,-2396570,1777923,0,-2858757,-2858757,,-92313,,,,-122794,0,2858757,0,339393,,-2396570,-2396570,154900834.0,230823367.0,10903132.0,164230236.0,175133368.0,4664.0,-66584768.0,2755034.0,11640000.0,-13027.0,137550.0,5965661.0,832177.0,-13027.0,2389451.0,6065533.0,5854765.0,282376.0,,,-310501.0,-122464.0,-40408.0,-119749.0,82056.0,-2730700.0,24965.0,-2755665.0,30458.0,-35263.0,-10721.0,-10721.0,1982.0,5233356.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NCM,"Enochian Biosciences, Inc.",us_market,2,NasdaqCM,"Enochian Biosciences, Inc.",USD,2239195,448500,4.83,1.8576924,2.6 - 12.99,-5.56,-0.42802155,2.6,12.99,1589227200,1589227200,1589227200,-0.235,0,3.463,5.555278,1.874722,0.33746684,4.445942,2.984058,0.67118686,353767552,2.1455386,15,America/New_York,EDT,-14400000,False,False,0.6775029,7.34 - 7.5,7.38,7.44,7.49,8,12,finmb_549849556,7.43,1630509299,0.049999714,7.37,7.5,7.34,64273,0.3,,,12.99,2.6,5.56,4.45,2.24M,448.5k,47.61M,,18.29M,61.79%,5.03%,1.16M,3.87,9.96%,2.23%,1.09M,,,,,,0.00%,,,,,"Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-4.25%,-8.09%,,,,,-11.93M,-13.46M,-0.23,,4.53M,0.09,7.61M,4.69,3.49,3.46,-9.83M,-5.87M,Value,90067-2012,Healthcare,10,8,10,"Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",Los Angeles,786 888 1685,CA,2,1609372800,1625097600,10,United States,http://www.enochianbio.com,86400,9,Century City Medical Plaza,Biotechnology,Suite 906 2080 Century Park East
t-3,ENOB,-269062.0,47613400,1305353,,-4098161,,-4098161,1498114,0,-2833139,-2833139,,-92250,,,,0,0,2833139,0,-1265022,,-4098161,-4098161,154901323.0,230497225.0,11829798.0,166272261.0,178102059.0,4650.0,-64188198.0,3182434.0,11640000.0,-41416.0,137550.0,8696361.0,1334798.0,-41416.0,2481977.0,8941209.0,5780787.0,592877.0,,1982.0,264511.0,-122464.0,-40408.0,109249.0,82056.0,-2242805.0,12740.0,-2245097.0,18619.0,1384786.0,-10448.0,-10448.0,1920.0,7606411.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NCM,"Enochian Biosciences, Inc.",us_market,2,NasdaqCM,"Enochian Biosciences, Inc.",USD,2239195,448500,4.83,1.8576924,2.6 - 12.99,-5.56,-0.42802155,2.6,12.99,1589227200,1589227200,1589227200,-0.235,0,3.463,5.555278,1.874722,0.33746684,4.445942,2.984058,0.67118686,353767552,2.1455386,15,America/New_York,EDT,-14400000,False,False,0.6775029,7.34 - 7.5,7.38,7.44,7.49,8,12,finmb_549849556,7.43,1630509299,0.049999714,7.37,7.5,7.34,64273,0.3,,,12.99,2.6,5.56,4.45,2.24M,448.5k,47.61M,,18.29M,61.79%,5.03%,1.16M,3.87,9.96%,2.23%,1.09M,,,,,,0.00%,,,,,"Jun 29, 2020","Mar 30, 2021",0.00%,0.00%,-4.25%,-8.09%,,,,,-11.93M,-13.46M,-0.23,,4.53M,0.09,7.61M,4.69,3.49,3.46,-9.83M,-5.87M,Value,90067-2012,Healthcare,10,8,10,"Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.",Los Angeles,786 888 1685,CA,2,1609372800,1625097600,10,United States,http://www.enochianbio.com,86400,9,Century City Medical Plaza,Biotechnology,Suite 906 2080 Century Park East
